Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
Hyperkalemia, defined as elevated serum potassium levels exceeding 5.1 mmol/L (with some guidelines considering a threshold of 5.3 mmol/L or higher), is a significant clinical concern in primary care, particularly among patients with chronic kidney disease (CKD), heart failure, and those on renin-angiotensin-aldosterone system (RAAS) inhibitors. Its management is critical due to the associated risks of severe complications, including cardiac arrhythmias and increased mortality (Kövesdy, 2016; Bianchi et al., 2019). In primary care settings, hyperkalemia prevalence has been reported at approximately 5% to 6.3%, underscoring the need for vigilant monitoring and proactive management strategies (Sevamontree et al., 2024; Nicola et al., 2023).
Challenges in the outpatient management of hyperkalemia include ensuring the accuracy of potassium level measurements, addressing the potential for factitious hyperkalemia due to hemolysis, and implementing timely interventions (Chiu et al., 2023). Clinicians must be skilled in distinguishing between true hyperkalemia and falsely elevated readings to avoid unnecessary emergency referrals (Chiu et al., 2023). Management strategies are multifaceted, incorporating dietary modifications, pharmacological interventions such as potassium binders, and regular monitoring of serum potassium levels to effectively mitigate risks (Sarnowski et al., 2022; Son, 2024; AlSahow et al., 2024).
Why? Ensuring accurate lab results prevents unnecessary interventions.
Why? Potassium levels ≥ 6.0 mmol/L increase risk of arrhythmias.
Why? Helps contextualize results.
Why? Neuromuscular/cardiac symptoms need urgent care.
Why? ECG changes indicate cardiac instability.
Why? These drugs impair potassium excretion.
Why? CKD and heart failure affect potassium balance.
Why? Diet and supplements can worsen hyperkalemia.
Why? Impaired renal function reduces potassium excretion.
Why? Helps distinguish transient from chronic cases.
Why? Prevents mismanagement due to lab errors.
Why? Renal impairment contributes to hyperkalemia.
The management of hyperkalemia in primary care is a complex but essential aspect of patient care that necessitates a comprehensive understanding of its etiology, implications, and treatment options. The causes can be broadly seen as
Cause Category | Specific Causes/Subcategories | Description/Mechanism |
---|---|---|
Renal Dysfunction |
- Chronic Kidney Disease (CKD) - Acute Kidney Injury (AKI) - Congestive Heart Failure |
Impaired renal excretion of potassium due to reduced glomerular filtration rate (GFR ↓). CKD and AKI hinder the kidneys’ ability to eliminate potassium, while heart failure may further exacerbate renal impairment. |
Medication Effects |
- RAAS inhibitors (ACEIs, ARBs) - Potassium-sparing diuretics (e.g., spironolactone) - NSAIDs - Certain antibiotics |
These medications can decrease aldosterone activity or impair renal function, resulting in reduced potassium excretion and elevated serum potassium levels (↑). |
Metabolic/Endocrine Disturbances |
- Metabolic acidosis - Diabetic ketoacidosis - Adrenal insufficiency - Excessive potassium intake |
Acidosis causes a shift of potassium from intracellular to extracellular spaces (↑). Endocrine disorders, such as adrenal insufficiency, decrease aldosterone production (↓), and high potassium intake can overwhelm excretion mechanisms. |
Other Factors |
- Tissue trauma/Hemolysis - Pseudohyperkalemia |
Tissue injury or hemolysis releases intracellular potassium into the bloodstream (↑), while pseudohyperkalemia results from sample handling errors, leading to falsely elevated potassium readings. |
Agiro, A., Dwyer, J., Oluwatosin, Y., & Desai, P. (2023). Medical costs in patients with hyperkalemia on long‐term sodium zirconium cyclosilicate therapy: the RECOGNIZE II study. Clinicoeconomics and Outcomes Research, 15, 691–702. https://doi.org/10.2147/ceor.s420217
AlSahow, A., Bulbanat, B., Al‐Helal, B., Alhumoud, K., Alkharaza, A., Al-Otaibi, T., … & Hadi, F. (2024). Management of hyperkalemia: expert consensus from Kuwait – a modified Delphi approach. International Journal of Nephrology and Renovascular Disease, 17, 227–240. https://doi.org/10.2147/ijnrd.s476344
Bianchi, S., Aucella, F., Nicola, L., Genovesi, S., Paoletti, E., & Regolisti, G. (2019). Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 32(4), 499–516. https://doi.org/10.1007/s40620-019-00617-y
Chiu, M., Garg, A., Moist, L., & Jain, A. (2023). A new perspective to longstanding challenges with outpatient hyperkalemia: a narrative review. Canadian Journal of Kidney Health and Disease, 10. https://doi.org/10.1177/20543581221149710
Imamura, T., Narang, N., & Kinugawa, K. (2023). Financial implication of sodium zirconium cyclosilicate therapy in patients with systolic heart failure and hyperkalemia. International Heart Journal, 64(6), 1065–1070. https://doi.org/10.1536/ihj.23-352
Kövesdy, C. (2016). Updates in hyperkalemia: outcomes and therapeutic strategies. Reviews in Endocrine and Metabolic Disorders, 18(1), 41–47. https://doi.org/10.1007/s11154-016-9384-x
Nicola, L., Ferraro, P., Montagnani, A., Pontremoli, R., Dentali, F., & Sesti, G. (2023). Recommendations for the management of hyperkalemia in patients receiving renin–angiotensin–aldosterone system inhibitors. Internal and Emergency Medicine, 19(2), 295–306. https://doi.org/10.1007/s11739-023-03427-0
Sarnowski, A., Gama, R., Dawson, A., Mason, H., & Banerjee, D. (2022). Hyperkalemia in chronic kidney disease: links, risks and management. International Journal of Nephrology and Renovascular Disease, 15, 215–228. https://doi.org/10.2147/ijnrd.s326464
Sevamontree, C., Jintajirapan, S., Phakdeekitcharoen, P., & Phakdeekitcharoen, B. (2024). The prevalence and risk factors of hyperkalemia in the outpatient setting. International Journal of Nephrology, 2024, 1–9. https://doi.org/10.1155/2024/5694131
Silva‐Cardoso, J., Brito, D., Frazão, J., Ferreira, A., Bettencourt, P., Branco, P., … & Fonseca, C. (2021). Management of RAAS-associated hyperkalemia in patients with cardiovascular disease. Heart Failure Reviews, 26(4), 891–896. https://doi.org/10.1007/s10741-020-10069-3
Son, H. (2024). Management strategies for potassium levels during non-steroidal mineralocorticoid receptor antagonist therapy: a comprehensive review. Electrolytes & Blood Pressure, 22(2), 29. https://doi.org/10.5049/ebp.2024.22.2.29
Varallo, F., Trombotto, V., Lucchetta, R., & Mastroianni, P. (2019). Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review. Pharmacy Practice, 17(1), 1361. https://doi.org/10.18549/pharmpract.2019.1.1361
Abbas, S., Ihle, P., Harder, S., & Schübert, I. (2015). Risk of hyperkalemia and combined use of spironolactone and long‐term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real‐life data: a population‐ and insurance‐based cohort. Pharmacoepidemiology and Drug Safety, 24(4), 406–413. https://doi.org/10.1002/pds.3748
Agarwal, R., Joseph, A., Anker, S., Filippatos, G., Rossing, P., Ruilope, L., … & Bakris, G. (2022). Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. Journal of the American Society of Nephrology, 33(1), 225–237. https://doi.org/10.1681/asn.2021070942
Hunter, R. & Bailey, M. (2019). Hyperkalemia: pathophysiology, risk factors and consequences. Nephrology Dialysis Transplantation, 34(Supplement_3), iii2–iii11. https://doi.org/10.1093/ndt/gfz206
Kövesdy, C. (2016). Updates in hyperkalemia: outcomes and therapeutic strategies. Reviews in Endocrine and Metabolic Disorders, 18(1), 41–47. https://doi.org/10.1007/s11154-016-9384-x
Lindner, G., Burdmann, E., Clase, C., Hemmelgarn, B., Herzog, C., Małyszko, J., … & Singer, A. (2020). Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. European Journal of Emergency Medicine, 27(5), 329–337. https://doi.org/10.1097/mej.0000000000000691
Mohamed, S. (2022). Settings for hyperkalemic patients in the emergency department. International Journal of Health Sciences, 2681–2689. https://doi.org/10.53730/ijhs.v6ns8.12547
Morales, E., Cravedi, P., & Manrique, J. (2021). Management of chronic hyperkalemia in patients with chronic kidney disease: an old problem with new options. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.653634
Nguyen, P., Kataria, V., Sam, T., Hooper, K., & Mehta, A. (2021). Comparison of patiromer to sodium polystyrene sulfonate in acute hyperkalemia. Hospital Pharmacy, 57(3), 359–364. https://doi.org/10.1177/00185787211037552
Thomsen, R., Nicolaisen, S., Hasvold, P., García‐Sánchez, R., Pedersen, L., Adelborg, K., … & Sørensen, H. (2018). Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes. Journal of the American Heart Association, 7(11). https://doi.org/10.1161/jaha.118.008912
Wang, Y., Ren, Q., Luo, H., Chen, G., Zhao, B., & Li, X. (2023). A real-world analysis of post-marketing surveillance data assessing the incidence of hyperkalemia or acute kidney injury in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers. Reviews in Cardiovascular Medicine, 24(4). https://doi.org/10.31083/j.rcm2404107
Weir, M. (2016). Current and future treatment options for managing hyperkalemia. Kidney International Supplements, 6(1), 29–34. https://doi.org/10.1016/j.kisu.2016.01.005